CJC-1295 DAC: Complete Research Guide — Extended Half-Life GHRH Analog for Growth Hormone Research
Shop Our Top Compounds
For research purposes only. Not for human consumption.
Introduction to CJC-1295 DAC Research
CJC-1295 DAC is a synthetic analog of growth hormone releasing hormone (GHRH) that has fundamentally reshaped how researchers approach sustained growth hormone stimulation in experimental models. Developed by ConjuChem Biotechnologies, this long-acting releasing hormone GHRH analog uses a proprietary Drug Affinity Complex to extend its functional half life from minutes to approximately 6–8 days in healthy adults. The result is prolonged stimulation of the growth hormone axis that maintains elevated growth hormone levels and insulin like growth factor concentrations for extended periods following a single injection.
Published clinical data from randomized, placebo-controlled trials have demonstrated that CJC-1295 DAC can elevate plasma growth hormone concentrations 2- to 10-fold for six or more days and increase circulating average IGF I levels 1.5- to 3-fold for 9–11 days. These findings have positioned CJC-1295 DAC as one of the most extensively studied GHRH analogs in the research literature, with applications spanning body composition analysis, fat loss investigation, protein synthesis research, and pituitary gland function studies.
This guide provides a comprehensive review of CJC-1295 DAC research, encompassing the CJC-1295 DAC mechanism of action, Drug Affinity Complex technology, pharmacokinetic data, clinical findings, safety profiles, and the synergistic potential of combining CJC-1295 with growth hormone releasing peptide compounds in peptide therapy investigation. All content is presented for research and educational purposes only.
Discovery and Development of CJC-1295 DAC
From Native GHRH to Engineered Stability
Growth hormone releasing hormone was first characterized in 1982 as a 44-amino acid hypothalamic peptide that binds to receptors on pituitary somatotrophs, stimulating both the synthesis and pulsatile release of growth hormone. Researchers established that the biological activity of releasing hormone GHRH resides within its first 29 amino acid residues — the fragment known as GHRH(1-29) or GRF(1-29).
However, native GHRH(1-29) has a plasma half life of only 7–10 minutes due to rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV). This prompted research into modified releasing hormone GHRH analogs with enhanced metabolic function and stability. Sermorelin, the first clinically approved analog, offered improved stability but still required daily administration.
The ConjuChem Bioconjugation Approach
The development of CJC-1295 DAC represented a paradigm shift. Rather than simply modifying amino acid residues to resist enzymatic degradation, researchers at ConjuChem introduced a reactive chemical moiety — the Drug Affinity Complex — that enables the peptide to bind covalently to circulating serum albumin after subcutaneous injection.
The foundational preclinical work was published by Jetté et al. in 2005, who demonstrated that hGRF(1-29)-albumin bioconjugates retained full GRF receptor binding capacity and biological activity at the anterior pituitary in rat models. CJC-1295 was identified as the lead compound, confirming that covalent albumin conjugation did not impair receptor pharmacology while dramatically extending plasma residence time.
CJC-1295 DAC incorporates four strategic amino acid substitutions in the GHRH(1-29) backbone — at positions 2, 8, 15, and 27 — that confer resistance to DPP-IV cleavage and enhance receptor binding affinity. The DAC moiety is attached at a lysine residue, providing the reactive maleimide group that forms the albumin bond.
Jetté L, Léger R, Thibaudeau K, et al. “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.” Endocrinology, 146(7), 3052–3058, 2005.
Drug Affinity Complex Technology Explained
How the DAC Moiety Achieves Half Life Extension
The Drug Affinity Complex is a proprietary chemical linker technology designed to exploit the unique properties of human serum albumin for pharmacokinetic extension. Human serum albumin is the most abundant plasma protein, with a circulatory persistence of approximately 19–21 days. By forming a covalent bond with this endogenous carrier, CJC-1295 with DAC effectively borrows albumin’s extraordinary longevity.
The DAC moiety contains a maleimido-propionic acid (MPA) reactive group that, upon subcutaneous injection, undergoes a rapid nucleophilic addition reaction with the free thiol group on Cysteine-34 of albumin. This forms a stable thioether bond, creating the CJC-1295–albumin conjugate protected from renal filtration and enzymatic degradation.
Mechanisms of Extended Half Life
Research has demonstrated that the CJC-1295 DAC mechanism of half life extension operates through several complementary pathways:
- Size exclusion from renal clearance — Free CJC-1295 (approximately 3.6 kDa) would be rapidly filtered by the kidneys. Conjugation to albumin (66.5 kDa) raises the effective molecular weight above the renal filtration threshold.
- FcRn-mediated recycling — Albumin is rescued from lysosomal degradation by the neonatal Fc receptor (FcRn), which binds albumin at acidic pH and recycles it back to the cell surface. The CJC-1295 conjugate benefits from this protective pathway.
- Steric protection from proteases — The albumin surface shields the conjugated peptide from circulating proteases, further reducing degradation.
The cumulative result is a plasma half life of approximately 5.8–8.1 days in subjects, as established in the landmark clinical trials by Teichman et al. (2006), published in the J Clin Endocrinol Metab. This represents an approximately 1,000-fold increase over the half life of native releasing hormone GHRH(1-29).
Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab, 91(3), 799–805, 2006.
GH Pulsatile Release Patterns Under CJC-1295 DAC
Preserved Pulsatility Despite Continuous Stimulation
One of the most significant findings in CJC-1295 DAC research is that the compound stimulates GH secretion while preserving the natural pulsatile pattern. Pulsatile secretion of growth hormone is considered essential for many physiological effects, including gene expression regulation, longitudinal bone growth, sleep quality support, and modulation of body composition.
Ionescu and Frohman (2006) conducted a landmark study assessing GH pulsatility in subjects aged 20–40 years following a single injection of CJC-1295 DAC. Using 20-minute blood sampling over a 12-hour overnight period, they found:
- GH pulsatility was preserved: The frequency and magnitude of GH pulses were unaltered by CJC-1295 administration.
- Basal GH levels increased 7.5-fold, representing the primary driver of elevated total output and continuous gh elevation throughout the study period.
- Mean GH concentrations increased by 46%, demonstrating significant growth hormone axis activation.
- Average IGF I levels increased by 45%, confirming sustained insulin like growth factor pathway activation.
These results indicate that CJC-1295 DAC amplifies GH output primarily by elevating interpulse trough concentrations rather than altering GH pulses frequency or amplitude. This preserves the somatostatin-mediated oscillatory control of natural gh release, fundamentally different from exogenous synthetic growth hormone administration.
Implications for Endogenous GH Secretion Research
The preservation of pulsatility under CJC-1295 DAC has important implications for endogenous gh secretion studies. Unlike direct GH administration, GHRH-mediated stimulation promotes the release of all endogenous GH isoforms from pituitary gland somatotrophs and supports the body’s own gh production mechanisms. This makes CJC-1295 DAC a valuable tool for studying natural GH surge dynamics and physiologically relevant secretory patterns in controlled experimental settings.
Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab, 91(12), 4792–4797, 2006.
CJC-1295 DAC vs CJC-1295 Without DAC: Research Comparison
Understanding the differences between CJC-1295 with DAC and Modified GRF 1-29 (also called CJC-1295 without DAC or Mod GRF) is essential for researchers selecting the appropriate synthetic analog for their experimental protocols in peptide therapy research.
Pharmacokinetic Differences
| Parameter | CJC-1295 DAC | CJC-1295 Without DAC (Mod GRF) |
|---|---|---|
| Half life | 5.8–8.1 days | ~30 minutes |
| Albumin binding | Covalent (via DAC moiety) | None |
| GH elevation duration | 6+ days per injection | 30–60 minutes per injection |
| IGF-1 elevation | 9–11 days | Hours |
| Administration frequency | Weekly or biweekly in studies | Multiple times daily in studies |
| GH pattern | Sustained trough elevation with preserved pulses | Acute pulse followed by return to baseline |
Pulsatile vs. Sustained Stimulation Models
CJC-1295 without DAC acts as a short-acting GH releasing hormone analog that produces a rapid, discrete natural gh surge at each administration — more closely mimicking a single endogenous GHRH burst. This creates a pronounced peak-and-trough pattern useful for studying growth patterns and acute dynamics.
CJC-1295 with DAC provides continuous GH releasing hormone receptor stimulation over days. While requiring fewer administrations, it raises trough growth hormone levels significantly. Research confirms pulsatility is preserved, but the overall exposure profile differs from the acute-pulse model of Mod GRF 1-29.
Selecting Between CJC-1295 With DAC and Without DAC
The selection between CJC-1295 with DAC and CJC-1295 without DAC depends on the research question. Studies requiring sustained, steady-state growth hormone and IGF-1 elevation benefit from the DAC formulation. Investigations focused on acute GH pulse dynamics or synergistic protocols with precisely timed GHRP co-administration may favor the no-DAC variant. Both forms are valuable GHRH analogs for research.
Clinical Trial Data: GH and IGF-1 Elevation
The Teichman et al. Ascending Dose Trials (2006)
The most comprehensive clinical dataset for CJC-1295 DAC comes from two randomized, placebo-controlled, double-blind ascending dose trials published by Teichman et al. These trials enrolled subjects aged 21–61 years and evaluated CJC-1295 DAC across multiple dose levels.
Study 1 — Single Dose Ascending: Subjects received a single subcutaneous injection at doses of 30, 60, 125, or 250 μg/kg. Key findings included:
- Dose-dependent increases in mean plasma growth hormone concentrations of 2- to 10-fold, sustained for 6+ days with peak growth hormone levels at 2–6 hours post-injection.
- Average IGF I levels increased 1.5- to 3-fold, remaining elevated for 9–11 days.
- The compound plasma persistence was estimated at 5.8–8.1 days.
Study 2 — Multiple Dose: Subjects received two or three weekly injections. Key findings included:
- After multiple doses, average IGF I levels remained above baseline for up to 28 days, with peak growth hormone levels accumulating over time.
- Evidence of a cumulative effect with repeated dosing, suggesting steady-state elevation could be achieved with regular administration.
- No serious adverse reactions were reported across either trial.
Serum Protein Profile and Biomarker Research
Sackmann-Sala et al. (2009) extended the analysis by examining serum proteomic changes following CJC-1295 DAC injection. Researchers identified five serum proteins that changed significantly following GH/IGF-1 axis activation, including apolipoprotein A1 and transthyretin alterations. A significant correlation was found between immunoglobulin fragments and IGF-1 levels, representing early growth response biomarker research.
Body Composition Research: Preclinical Evidence
Normalizing Growth in GHRH Knockout Mouse Models
Alba et al. (2006) provided compelling preclinical evidence for CJC-1295 DAC effects on body composition using the GHRH knockout mouse model — animals with complete ablation of the GHRH gene resulting in severe GH deficiency, dwarfism, and altered tissue distribution.
Three groups of one-week-old GHRHKO pups received CJC-1295 DAC at intervals of 24, 48, or 72 hours for five weeks. The once daily administration group showed remarkable results:
- CJC-1295 DAC normalizes growth: Daily administration restored body weight and length to levels comparable to GH-sufficient controls, demonstrating the compound can completely normalize growth in deficient models.
- Skeletal integrity preserved: Femur and tibia length remained normal, supporting healthy muscle and bone structure development.
- Lean mass and fat mass normalization: Relative lean body weight was restored while subcutaneous fat mass levels were corrected — indicating restored body composition profiles associated with adequate signaling and improved fat metabolism.
- Pituitary gland stimulation: CJC-1295 DAC increased total pituitary RNA and GH mRNA levels, with immunohistochemistry confirming somatotroph cell proliferation and elevated GH mRNA expression.
These findings established that a long-acting GHRH analog can restore growth patterns and normalize body composition in GH deficiency models through sustained receptor activation. CJC-1295 DAC normalizes growth parameters and supports natural growth hormone production pathways, making it a powerful research tool for investigating the GH/IGF-1 axis.
Alba M, Fintini D, Sagazio A, et al. “Once-daily administration of CJC-1295, a long-acting growth hormone releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” Am J Physiol Endocrinol Metab, 291(6), E1290–E1294, 2006.
Fat Loss, Lean Mass, and Muscle Growth Research
GH/IGF-1 Axis and Fat Metabolism
The growth hormone/IGF-1 axis plays a well-established role in regulating body composition and fat metabolism throughout the lifespan. Age-related declines in GH output — a phenomenon termed the “somatopause” — are associated with increased fat mass (particularly visceral adiposity and elevated fat tissue levels), decreased lean mass, reduced bone mineral density, and impaired metabolic function.
Research has demonstrated that restoring GH/IGF-1 axis activity through GHRH analogs can promote fat loss and improve body composition parameters. CJC-1295 DAC research offers a unique framework because GHRH-mediated stimulation preserves pulsatile dynamics and the body’s own gh output, unlike exogenous therapy. Growth hormone stimulates lipolysis through activation of hormone-sensitive lipase, increasing free fatty acids mobilization from adipose tissue and enhancing overall fat loss potential in research models.
Muscle Growth, Protein Synthesis, and Tissue Remodeling
Growth hormone and its downstream mediator IGF-1 are potent stimulators of protein synthesis, myogenesis, and muscle hypertrophy through multiple cellular signaling pathways. GH activates the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway upon binding GH receptors on target tissues including liver cells and skeletal muscle. This signaling cascade stimulates hepatic IGF-1 production, which in turn drives:
- Protein synthesis upregulation via mTOR pathway activation, supporting increased muscle mass and muscle hypertrophy in experimental models
- Satellite cell activation contributing to lean muscle growth and muscle growth in research contexts
- Collagen synthesis enhancement for connective tissue integrity and muscle and bone structure support
- Nitrogen retention and protein synthesis promoting favorable tissue remodeling and fat loss
Because CJC-1295 DAC promotes endogenous GH output rather than supplying exogenous hormone, research models can investigate how sustained GHRH receptor activation influences protein synthesis, muscle hypertrophy, and tissue remodeling through physiological signaling — an important area of peptide therapy research.
Sleep Quality and Growth Hormone Research
Slow Wave Sleep and Nocturnal GH Dynamics
GH output is closely linked to sleep quality, with the largest natural gh surge occurring during slow wave sleep (deep sleep stages 3 and 4). Research has demonstrated that approximately 70% of daily GH output in young adults occurs during slow wave sleep periods, mediated by hypothalamic releasing hormone GHRH acting on the pituitary gland.
CJC-1295 DAC research is of interest to sleep and neuroendocrine investigators because the compound’s sustained receptor activation may influence both sleep quality and nighttime secretory patterns. The interaction between GHRH signaling and sleep architecture represents an active area of investigation, with GHRH itself shown to promote deep sleep through neuronal function modulation in the hypothalamus.
Cellular Signaling and Receptor Pathways
GHRH Receptor Signaling Through G Protein Coupled Receptors
The GHRH receptor belongs to the class B family of G protein coupled receptors expressed on pituitary somatotrophs. When CJC-1295 DAC activates these receptors, it stimulates adenylyl cyclase through Gsα, increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. This cascade proceeds to activate protein kinases — specifically protein kinase A (PKA) — which stimulates GH gene transcription, GH mRNA expression, and vesicle exocytosis for GH release.
The cAMP/PKA pathway also supports somatotroph proliferation and transcript maintenance. Research with CJC-1295 DAC in the GHRHKO model confirmed increased total pituitary RNA, elevated GH mRNA levels, and somatotroph hyperplasia — demonstrating that sustained GHRH stimulation through this synthetic analog supports both acute GH release and long-term pituitary remodeling as a form of hormone optimization.
Safety and Immunogenicity Data
Clinical Safety Profile of CJC-1295 DAC
Across published clinical trials, CJC-1295 DAC demonstrated a generally favorable safety profile at the dose levels studied. Teichman et al. (2006) reported:
- No serious adverse reactions across single-dose or multiple-dose trials.
- Common adverse events included mild injection site reactions, headache, diarrhea, and flushing/warmth.
- Higher doses (250 μg/kg) produced moderate adverse events that resolved spontaneously.
- Doses of 30 and 60 μg/kg were described as safe and well tolerated.
Immunogenicity Considerations
Immunogenicity is an inherent concern with peptide therapeutics forming covalent bonds with endogenous proteins. The CJC-1295–albumin conjugate creates a neoantigenic surface the immune system may recognize. Clemmons (2007) reviewed CJC-1295 DAC noting that while results were promising, concerns about immunogenicity and systemic vasodilatory responses warranted further investigation. This unknown pharmaceutical preparation aspect of the albumin conjugate requires specific safety monitoring in any CJC-1295 DAC research protocol.
Synergy with Growth Hormone Peptides in Research
The GHRH-GHRP Synergistic Axis
One of the most compelling areas of CJC-1295 DAC research involves its potential synergy with growth hormone peptides — specifically growth hormone releasing peptide compounds that stimulate GH output through ghrelin receptors (GHS-R1a) via a separate intracellular signaling cascade. Growth hormone secretagogues including GHRP-6, GHRP-2, hexarelin, and ipamorelin act through this distinct pathway.
Published research has demonstrated that the effects of GHRH and growth hormone releasing peptide compounds are synergistic rather than additive. This synergy is attributed to complementary mechanisms:
- GHRH activates the cAMP/PKA pathway, directly stimulating GH gene transcription and GH release from somatotrophs.
- GHRPs activate the phospholipase C/IP3/DAG pathway, binding ghrelin receptors to mobilize intracellular calcium stores and amplify GHRH-initiated signaling.
- GHRPs suppress somatostatin tone, reducing the inhibitory brake on GH release and supporting natural growth hormone production.
Research Protocols Combining CJC-1295 DAC and Growth Hormone Peptides
In research settings, combinations of CJC-1295 DAC and growth hormone peptides such as ipamorelin have been studied for their ability to produce robust output through dual-pathway stimulation. Ipamorelin has attracted interest due to its selectivity and minimal effects on cortisol and prolactin, making it a cleaner tool for studying GH-specific growth response patterns and hormone optimization strategies.
The sustained GHRH tone from CJC-1295 with DAC may create an optimal background for GHRP-mediated GH pulses, leveraging the complementary cellular signaling pathways to maximize GH release while preserving pulsatile characteristics important for physiological action.
Bowers CY. “Growth hormone-releasing peptide (GHRP).” Cellular and Molecular Life Sciences, 54(12), 1316–1329, 1998.
Research Applications and Future Directions
Peptide Therapy Research With CJC-1295 DAC
CJC-1295 DAC continues to serve as an essential tool across multiple areas of peptide therapy research:
- Body composition studies: Investigating the effects of sustained GH/IGF-1 axis activation on fat loss, tissue accrual, and fat metabolism regulation.
- Aging and somatopause research: Evaluating whether GHRH analogs can restore age-related declines and address GH deficiency in experimental models.
- Pituitary function studies: Examining somatotroph responsiveness, GH transcript expression, and neuronal function in neuroendocrine models.
- Synergistic peptide protocols: Exploring combinations with growth hormone peptides and growth hormone secretagogues to optimize output through complementary receptor pathways.
- Biomarker discovery: Identifying serum protein changes associated with GH/IGF-1 axis activation for improved outcome monitoring.
The Role of CJC-1295 in Modern Research
As peptide therapy research advances, CJC-1295 DAC remains at the forefront. Its unique mechanism — covalent albumin binding through DAC technology — provides researchers a tool that achieves sustained GH release while preserving physiological pulsatility. This distinguishes CJC-1295 from other approaches and positions it as a reference compound for evaluating next-generation releasing hormone GHRH derivatives.
Frequently Asked Questions About CJC-1295 DAC
What is CJC-1295 DAC?
CJC-1295 DAC is a synthetic analog of growth hormone releasing hormone engineered with the DAC moiety that enables covalent binding to serum albumin. While native GHRH has a plasma duration of 7–10 minutes, CJC-1295 DAC achieves a half life of approximately 5.8–8.1 days. This peptide is available for research purposes only.
What does DAC stand for?
DAC stands for Drug Affinity Complex, a proprietary technology from ConjuChem Biotechnologies. The DAC moiety contains a reactive maleimide group that forms a covalent bond with Cysteine-34 of endogenous serum albumin after injection, dramatically extending the plasma duration of CJC-1295.
How does CJC-1295 DAC affect GH pulses and secretory patterns?
Published research demonstrates that CJC-1295 DAC preserves the natural pulsatile pattern. GH pulses frequency and amplitude remain unchanged, while basal trough levels increase 7.5-fold. CJC-1295 DAC amplifies GH secretion through trough elevation rather than pulse alteration.
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 with DAC has a half life of 5.8–8.1 days due to covalent albumin binding, providing sustained stimulation over days. CJC-1295 without DAC has a duration of approximately 30 minutes, producing an acute pulse at each administration. CJC-1295 with DAC suits research requiring steady-state elevation, while the no-DAC version is preferred for acute dynamic studies.
What clinical trial data exists for CJC-1295 DAC?
The Teichman et al. (2006) ascending dose trials demonstrated dose-dependent growth hormone increases of 2- to 10-fold sustained for 6+ days. Insulin like growth factor I concentrations rose 1.5- to 3-fold for 9–11 days. After multiple doses, IGF-1 remained elevated for up to 28 days, demonstrating cumulative effects from this GHRH analog.
Can CJC-1295 DAC support fat loss research?
CJC-1295 DAC research has implications for fat loss investigation through sustained GH/IGF-1 axis activation. Growth hormone promotes lipolysis and mobilization of free fatty acids from fat tissue levels in adipose stores. Effects on body composition — including reduced fat mass and increased lean mass — have been documented in preclinical models, making CJC-1295 DAC valuable for fat loss and lipid metabolism research.
Is CJC-1295 DAC combined with GHRP peptides?
Yes, combining CJC-1295 DAC with GHRP compounds like ipamorelin is an active area of peptide therapy research. GHRH and GHRP act through distinct receptor pathways — GHRH-R and GHS-R1a respectively — producing synergistic effects when combined. This dual-pathway approach is studied extensively in GH research.
Where can researchers obtain CJC-1295 DAC?
CJC-1295 DAC is available from specialized research peptide suppliers. Iron Peak Peptides offers CJC-1295 DAC 5mg with third-party purity testing for laboratory use. All products are sold strictly for research purposes — not for human consumption.
Conclusion
CJC-1295 DAC research represents one of the most thoroughly characterized applications of half life extension technology in peptide therapy and endocrinology. From the foundational bioconjugate work by Jetté et al. (2005) through the landmark clinical trials by Teichman et al. (2006), published in the J Clin Endocrinol Metab, the evidence establishes CJC-1295 DAC as a potent, long-acting releasing hormone GHRH analog capable of producing sustained, dose-dependent increases in growth hormone and IGF-1 while preserving pulsatile GH secretion patterns.
The CJC-1295 DAC mechanism — leveraging covalent albumin binding through the Drug Affinity Complex — achieves a half life of approximately 6–8 days. Preclinical data demonstrate normalization of tissue distribution in GH deficiency models, while proteomic studies have identified potential biomarkers of GH/IGF-1 axis activation. For researchers investigating fat loss, protein synthesis, muscle growth, or GHRH-GHRP synergistic pathways, CJC-1295 DAC remains an essential investigational tool.
Explore Iron Peak Peptides’ research-grade CJC-1295 DAC and other growth hormone peptides to support your laboratory investigations. For definitions of technical terms, visit the Peptide Glossary.
Research Disclaimer
This article is for educational and informational purposes only. All content reflects published scientific research intended exclusively for researchers and academic professionals.
CJC-1295 DAC is a research compound not approved for human therapeutic use by the FDA or any regulatory agency. This article does not constitute medical advice or dosage guidance.
All compounds discussed in this article are intended for research purposes only and are not for human consumption.
🔬 Explore Research Peptides
- Pinealon — $60.00
- Prostamax 20mg — $65.00
- PEG-MGF 2mg — $55.00
- Growth Hormone Research Stack — $129.00
